High-Time Chemotherapy or High Time for Low Dose
- 16 August 2000
- journal article
- editorial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 18 (16), 2935-2937
- https://doi.org/10.1200/jco.2000.18.16.2935
Abstract
No abstract availableThis publication has 21 references indexed in Scilit:
- Chemotherapeutic drugs—more really is not betterNature Medicine, 2000
- Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in miceJCI Insight, 2000
- Conventional-Dose Chemotherapy Compared with High-Dose Chemotherapy plus Autologous Hematopoietic Stem-Cell Transplantation for Metastatic Breast CancerNew England Journal of Medicine, 2000
- Aquaporins and the respiratory system: advice for a lung investigatorJCI Insight, 2000
- Angiogenesis in Neuroblastoma: Relationship to Survival and Other Prognostic Factors in a Cohort of Neuroblastoma PatientsJournal of Clinical Oncology, 2000
- Treatment of High-Risk Neuroblastoma with Intensive Chemotherapy, Radiotherapy, Autologous Bone Marrow Transplantation, and 13-cis-Retinoic AcidNew England Journal of Medicine, 1999
- Double dose-intensive chemotherapy with autologous stem-cell support for metastatic breast cancer: no improvement in progression-free survival by the sequence of high-dose melphalan followed by cyclophosphamide, thiotepa, and carboplatin.Journal of Clinical Oncology, 1996
- Shifting the cancer paradigm: must we kill to cure?Journal of Clinical Oncology, 1995
- Back to the basics: the importance of concentration x time in oncology.Journal of Clinical Oncology, 1993
- Inhibition of in vitro vascular endothelial cell proliferation and in vivo neovascularization by low‐dose methotrexateArthritis & Rheumatism, 1989